These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32772560)

  • 1. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing.
    Rizzo A; Ricci AD; Brandi G
    Future Oncol; 2020 Nov; 16(32):2587-2589. PubMed ID: 32772560
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.
    Zhong JH; Zhong QL; Li LQ; Li H
    Tumour Biol; 2014 Oct; 35(10):9459-68. PubMed ID: 25119592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.
    Brown ZJ; Greten TF; Heinrich B
    Hepatology; 2019 Oct; 70(4):1437-1442. PubMed ID: 30927283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis.
    Zhu GQ; Shi KQ; Yu HJ; He SY; Braddock M; Zhou MT; Chen YP; Zheng MH
    Oncotarget; 2015 Jul; 6(20):18151-61. PubMed ID: 26061709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
    Yegin EG; Oymaci E; Karatay E; Coker A
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the treatment of hepatocellular carcinoma on the waiting list necessary?
    Majno P; Lencioni R; Mornex F; Girard N; Poon RT; Cherqui D
    Liver Transpl; 2011 Oct; 17 Suppl 2():S98-108. PubMed ID: 21954097
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatocellular carcinoma (HCC): an update.
    Rougier P; Mitry E; Barbare JC; Taieb J
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S12-20. PubMed ID: 17449346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?
    Dikilitas M
    J Gastrointest Cancer; 2020 Dec; 51(4):1193-1196. PubMed ID: 32869146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative therapy options for hepatocellular carcinoma.
    Zhong JH; Ma L; Li LQ
    Scand J Gastroenterol; 2014 Jun; 49(6):649-61. PubMed ID: 24716523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.
    Fields TD; Philips P; Scoggins CR; Tatum C; Kelly L; McMasters KM; Martin RCG
    World J Surg; 2017 May; 41(5):1331-1339. PubMed ID: 27905019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hepatocellular carcinoma.
    Lau WY
    J R Coll Surg Edinb; 2002 Feb; 47(1):389-99. PubMed ID: 11874260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
    Yoon HI; Seong J
    Oncology; 2014; 87 Suppl 1():90-8. PubMed ID: 25427739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review.
    Lau WY; Lai EC; Lau SH
    Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):124-33. PubMed ID: 19357024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma: a systematic review and a meta-analysis.
    Lin HS; Wan RH; Gao LH; Li JF; Shan RF; Shi J
    Hepatobiliary Pancreat Dis Int; 2015 Jun; 14(3):236-45. PubMed ID: 26063023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel systemic therapy options for hepatocellular carcinoma.
    Cusnir M; Patt YZ
    Cancer J; 2004; 10(2):97-103. PubMed ID: 15130269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
    Zhang DZ; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pre- and/or postoperative adjuvant therapy for hepatocellular carcinoma].
    Imaoka S; Sasaki Y
    Nihon Geka Gakkai Zasshi; 1998 Apr; 99(4):229-33. PubMed ID: 9642691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of pediatric hepatocellular carcinoma: A multimodal approach.
    Kohorst MA; Warad DM; Matsumoto JM; Heimbach JK; El-Youssef M; Arndt CAS; Rodriguez V; Nageswara Rao AA
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28631359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
    Wang Z; Zhang G; Wu J; Jia M
    Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives.
    Su YY; Li CC; Lin YJ; Hsu C
    Semin Liver Dis; 2021 Aug; 41(3):263-276. PubMed ID: 34130338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.